Table 2.
Sample | Outcome | Variables | Odds-Ratio | β | Lower 95% CIs | Upper 95% CIs | P-value | DIC | AIC | R2 |
---|---|---|---|---|---|---|---|---|---|---|
GS:SFHS | MDD | Age | 1.00 | – | 0.99 | 1.01 | 9.71 × 10−2 | 12,561.35 | – | – |
Sex (F) | 1.71 | – | 1.48 | 1.97 | < 1.00 × 10−4 | |||||
Neuroticism | 3.71 | – | 3.37 | 4.12 | < 1.00 × 10−4 | |||||
g | 1.14 | – | 1.07 | 1.20 | < 1.00 × 10−4 | |||||
Neuroticism*g | 1.03 | – | 0.98 | 1.08 | 0.32 | |||||
UK Biobank | MDD | Age | 0.98 | – | 0.99 | 0.99 | < 2.00 × 10−16 | – | 98,785 | – |
Sex (F) | 1.34 | – | 1.32 | 1.36 | < 2.00 × 10−16 | |||||
Neuroticism | 2.40 | – | 2.36 | 2.44 | < 2.00 × 10−16 | |||||
g | 1.06 | – | 1.04 | 1.07 | 5.08 × 10−14 | |||||
Neuroticism*g | 0.96 | – | 0.95 | 0.98 | < 1.09 × 10−7 | |||||
GS:SFHS | GHQ | Age | – | 0.00 | −0.00 | 0.00 | 0.59 | 47,873.87 | – | – |
Sex (F) | – | 0.04 | 0.02 | 0.07 | 2.63 × 10−3 | |||||
Neuroticism | – | 0.50 | 0.49 | 0.52 | < 1.00 × 10−4 | |||||
g | – | −0.04 | −0.05 | −0.03 | < 1.00 × 10−4 | |||||
Neuroticism*g | – | −0.05 | −0.06 | −0.04 | < 1.00 × 10−4 | |||||
UK Biobank | PHQ | Age | – | −0.02 | −0.02 | −0.01 | < 2.00 × 10−16 | – | – | 0.2976 |
Sex (F) | – | −0.02 | −0.02 | −0.01 | 1.57 × 10−8 | |||||
Neuroticism | – | 0.51 | 0.51 | 0.52 | < 2.00 × 10−16 | |||||
g | – | −0.05 | −0.06 | −0.05 | < 2.00 × 10−16 | |||||
Neuroticism*g | – | −0.02 | −0.03 | −0.02 | < 2.00 × 10−16 |
MCMC: Markov Chain Monte Carlo; GS:SFHS: Generation Scotland: the Scottish Family Health Study; GHQ: General Health Questionnaire; DIC: Deviance Information Criterion; g: General Intelligence; MDD: major depressive disorder; PHQ: Patient Health Questionnaire; AIC: Akaike Information Criterion.